Anuj Singh
Research Subjects
Anuj Singh has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Nita Radhakrishnan
Department of Pediatric Hematology Oncology, Post Graduate Institute of Child Health, Noida, India
9 shared publications - Aditi Tulsiyan
Department of Pediatric Hematology Oncology, Post Graduate Institute of Child Health, Noida, India
7 shared publications - Sudipto Bhattacharya
Department of Pediatric Hematology Oncology, Post Graduate Institute of Child Health, Noida, India
6 shared publications - Hari Gaire
Department of Pediatric Hematology Oncology, Post Graduate Institute of Child Health, Noida, 201303, India
5 shared publications - Archit Pandharipande
Department of Clinical Hematology, AIIMS Nagpur, Nagpur, India
3 shared publications - Deeksha Bhalla
Department of Radiodiagnosis and Interventional Radiology, All India Institute of Medical Sciences, New Delhi, India
2 shared publications
Latest Publications
- 12 August 2026
- Published by Springer Nature in International Journal of Hematology
- Vol. 124 (5) , 741-746
Metabolic mimic of inherited bone marrow failure: LMBRD1 (cblF) deficiency in an infant
- 12 August 2026
- Published by Springer Nature in International Journal of Hematology
- Vol. 124 (5) , 741-746
Metabolic mimic of inherited bone marrow failure: LMBRD1 (cblF) deficiency in an infant
- Open Access
- 7 August 2026
- Published by Elsevier in Pediatric Hematology Oncology Journal
- Vol. 11 (3)
Prospective outcomes of peripherally inserted central catheters in pediatric hematology oncology and bone marrow transplantation: Insights from a resource constrained setting
- 7 August 2026
- Published by Elsevier in Pediatric Hematology Oncology Journal
- Vol. 11 (3)
Open AccessProspective outcomes of peripherally inserted central catheters in pediatric hematology oncology and bone marrow transplantation: Insights from a resource constrained setting
- Open Access
- 1 June 2026
- Published by Elmer Press, Inc. in Journal of Hematology
- Vol. 15 (3) , 156-161
Patterns and Outcomes of Recurrence in Pediatric Langerhans Cell Histiocytosis
- 1 June 2026
- Published by Elmer Press, Inc. in Journal of Hematology
- Vol. 15 (3) , 156-161
Open AccessPatterns and Outcomes of Recurrence in Pediatric Langerhans Cell Histiocytosis
- Open Access
- 30 March 2026
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 8 (2) , 213-218
Sepsis and Liver Abscess Caused by Leuconostoc mesenteroides in a Pediatric Patient with Aplastic Anemia
Aplastic anemia is a potentially life-threatening condition characterized by bone marrow failure, leading to severe pancytopenia and an increased risk of bacterial and fungal infections. The management of such infections is challenging in immunocompromised patients, particularly in the absence of definitive guidelines. We report a case of a 10-year-old boy with very severe aplastic anemia who developed sepsis and a liver abscess due to Leuconostoc mesenteroides. The infection resolved only after improvement of the absolute neutrophil count following hematopoietic stem cell transplantation. Because this organism is intrinsically resistant to vancomycin, treatment may require prolonged therapy with aminoglycosides, chloramphenicol, macrolides and other active agents. This case highlights the importance of considering rare pathogens such as L. mesenteroides in immunocompromised patients with persistent infections. Keywords: Leuconostoc mesenteroides, sepsis, liver abscess, severe aplastic anemia
- 30 March 2026
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 8 (2) , 213-218
Open AccessSepsis and Liver Abscess Caused by Leuconostoc mesenteroides in a Pediatric Patient with Aplastic Anemia
Aplastic anemia is a potentially life-threatening condition characterized by bone marrow failure, leading to severe pancytopenia and an increased risk of bacterial and fungal infections. The management of such infections is challenging in immunocompromised patients, particularly in the absence of definitive guidelines. We report a case of a 10-year-old boy with very severe aplastic anemia who developed sepsis and a liver abscess due to Leuconostoc mesenteroides. The infection resolved only after improvement of the absolute neutrophil count following hematopoietic stem cell transplantation. Because this organism is intrinsically resistant to vancomycin, treatment may require prolonged therapy with aminoglycosides, chloramphenicol, macrolides and other active agents. This case highlights the importance of considering rare pathogens such as L. mesenteroides in immunocompromised patients with persistent infections. Keywords: Leuconostoc mesenteroides, sepsis, liver abscess, severe aplastic anemia
- 26 March 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (6) , e70281
Dermatofibrosarcoma Protuberans in Infancy: Targeted Therapy Facilitating Complete Resection
- 26 March 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (6) , e70281
Dermatofibrosarcoma Protuberans in Infancy: Targeted Therapy Facilitating Complete Resection
- 26 February 2026
- Published by Springer Nature in International Journal of Hematology
- Vol. 124 (1) , 126-135
Managing massive gastrointestinal and abdominal haemorrhage in inherited bleeding disorders: experience from a pediatric cohort
Massive gastrointestinal (GI), intraperitoneal, and pelvic hemorrhage in inherited bleeding disorders (IBDs) is rare but potentially life-threatening. Pediatric data remain limited. We retrospectively reviewed patients ≤ 18 years with hemophilia A/B, von Willebrand disease (VWD), or rare bleeding disorders admitted with massive abdominal hemorrhage (September 2017-August 2025). Massive GI bleeding was defined as overt bleeding with estimated loss > 70 mL/kg/day or bleeding resulting in shock or transfusion. Intraperitoneal and pelvic hemorrhage required imaging confirmation. Demographics, interventions, and outcomes were analyzed and compared with the pediatric IBD cohort. Of 788 pediatric IBD patients, 10 (1.2%) developed massive abdominal hemorrhage: GI (n = 5), intraperitoneal (n = 3), and pelvic hematoma (n = 2). The GI bleeding cohort was older than the pediatric IBD cohort (median 16 vs. 8 years, p < 0.001). Diagnoses included hemophilia A (n = 4; 75% inhibitor-positive), hemophilia B (n = 1), VWD (n = 4), and Glanzmann thrombasthenia (n = 1). Seven required transfusions; four met massive transfusion criteria. Endoscopy identified a bleeding source in 80% of GI bleeds. Diagnostic delays were longer for intraperitoneal hemorrhage than for GI bleeds (p < 0.05). Massive abdominal haemorrhage causes significant morbidity. Early imaging, endoscopy, and aggressive hemostatic therapy resulted in 100% survival. Improved access to prophylaxis may prevent such events.
- 26 February 2026
- Published by Springer Nature in International Journal of Hematology
- Vol. 124 (1) , 126-135
Managing massive gastrointestinal and abdominal haemorrhage in inherited bleeding disorders: experience from a pediatric cohort
Massive gastrointestinal (GI), intraperitoneal, and pelvic hemorrhage in inherited bleeding disorders (IBDs) is rare but potentially life-threatening. Pediatric data remain limited. We retrospectively reviewed patients ≤ 18 years with hemophilia A/B, von Willebrand disease (VWD), or rare bleeding disorders admitted with massive abdominal hemorrhage (September 2017-August 2025). Massive GI bleeding was defined as overt bleeding with estimated loss > 70 mL/kg/day or bleeding resulting in shock or transfusion. Intraperitoneal and pelvic hemorrhage required imaging confirmation. Demographics, interventions, and outcomes were analyzed and compared with the pediatric IBD cohort. Of 788 pediatric IBD patients, 10 (1.2%) developed massive abdominal hemorrhage: GI (n = 5), intraperitoneal (n = 3), and pelvic hematoma (n = 2). The GI bleeding cohort was older than the pediatric IBD cohort (median 16 vs. 8 years, p < 0.001). Diagnoses included hemophilia A (n = 4; 75% inhibitor-positive), hemophilia B (n = 1), VWD (n = 4), and Glanzmann thrombasthenia (n = 1). Seven required transfusions; four met massive transfusion criteria. Endoscopy identified a bleeding source in 80% of GI bleeds. Diagnostic delays were longer for intraperitoneal hemorrhage than for GI bleeds (p < 0.05). Massive abdominal haemorrhage causes significant morbidity. Early imaging, endoscopy, and aggressive hemostatic therapy resulted in 100% survival. Improved access to prophylaxis may prevent such events.
- Open Access
- 5 February 2026
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 45
Long term outcomes of the Indian childhood cancer survivorship (C2S) cohort: a multicentre study (2016–2024)
- 5 February 2026
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 45
Open AccessLong term outcomes of the Indian childhood cancer survivorship (C2S) cohort: a multicentre study (2016–2024)
- Open Access
- 1 December 2025
- Published by Elmer Press, Inc. in Journal of Hematology
- Vol. 14 (6) , 307-313
Outcomes of Hematopoietic Stem Cell Transplantation Following the Use of Blinatumomab in Pediatric Relapsed B-Cell Acute Lymphoblastic Leukemia: A Single-Center Experience
Background: Relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) remains associated with poor outcomes in children. Achieving measurable residual disease (MRD) negativity prior to allogeneic hematopoietic stem cell transplantation (HSCT) is critical for durable remission. Blinatumomab, a bispecific CD19-CD3 T-cell engager, induces deep remissions with minimal myelosuppression and is increasingly utilized as a bridge to HSCT. We describe our institutional experience with HSCT following blinatumomab-induced remission in pediatric R/R B-ALL. Methods: This retrospective single-center study included five pediatric patients with R/R B-ALL who received blinatumomab bridging therapy prior to allogeneic HSCT between January 2020 and June 2025. Clinical data included demographics, prior therapies, blinatumomab dosing and duration, MRD status, conditioning regimen, donor source, stem cell dose, engraftment kinetics, donor chimerism, and complications. The endpoints included MRD clearance before HSCT, engraftment kinetics, donor chimerism, viral reactivation, bacterial infections post-transplant, and overall and failure-free survival at last follow-up. Results: All five patients completed one to two 28-day cycles of blinatumomab and achieved MRD negativity (< 0.01%) prior to HSCT. Donor sources comprised one matched sibling and four haploidentical family donors. The median interval between blinatumomab completion and HSCT was 32 days. Median neutrophil and platelet engraftment occurred on days +12 and +9, respectively. Full donor chimerism was achieved within 1 - 3 months and sustained throughout follow-up. Post-transplant complications included engraftment syndrome (n = 4), cytomegalovirus (CMV) reactivation (n = 4), Epstein-Barr virus (EBV) reactivation (n = 1), Clostridioides difficile enterocolitis (n = 1), and steroid-refractory acute graft-versus-host disease (GVHD) (n = 2). No transplant-related mortality was observed. At a median follow-up of 173 days (range, 52 - 1,015 days), all patients remained alive and in continuous complete remission with no active GVHD. Conclusions: In this single-center experience from a low-/middle-income country (LMIC), blinatumomab served as an effective bridge to HSCT, enabling MRD-negative remissions with favorable post-transplant outcomes. Viral reactivations and steroid-refractory GVHD were reported, underlining the need for robust surveillance. Broader access to blinatumomab and prospective studies are needed to validate these findings and to evaluate cost-effectiveness in LMICs.
- 1 December 2025
- Published by Elmer Press, Inc. in Journal of Hematology
- Vol. 14 (6) , 307-313
Open AccessOutcomes of Hematopoietic Stem Cell Transplantation Following the Use of Blinatumomab in Pediatric Relapsed B-Cell Acute Lymphoblastic Leukemia: A Single-Center Experience
Background: Relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) remains associated with poor outcomes in children. Achieving measurable residual disease (MRD) negativity prior to allogeneic hematopoietic stem cell transplantation (HSCT) is critical for durable remission. Blinatumomab, a bispecific CD19-CD3 T-cell engager, induces deep remissions with minimal myelosuppression and is increasingly utilized as a bridge to HSCT. We describe our institutional experience with HSCT following blinatumomab-induced remission in pediatric R/R B-ALL. Methods: This retrospective single-center study included five pediatric patients with R/R B-ALL who received blinatumomab bridging therapy prior to allogeneic HSCT between January 2020 and June 2025. Clinical data included demographics, prior therapies, blinatumomab dosing and duration, MRD status, conditioning regimen, donor source, stem cell dose, engraftment kinetics, donor chimerism, and complications. The endpoints included MRD clearance before HSCT, engraftment kinetics, donor chimerism, viral reactivation, bacterial infections post-transplant, and overall and failure-free survival at last follow-up. Results: All five patients completed one to two 28-day cycles of blinatumomab and achieved MRD negativity (< 0.01%) prior to HSCT. Donor sources comprised one matched sibling and four haploidentical family donors. The median interval between blinatumomab completion and HSCT was 32 days. Median neutrophil and platelet engraftment occurred on days +12 and +9, respectively. Full donor chimerism was achieved within 1 - 3 months and sustained throughout follow-up. Post-transplant complications included engraftment syndrome (n = 4), cytomegalovirus (CMV) reactivation (n = 4), Epstein-Barr virus (EBV) reactivation (n = 1), Clostridioides difficile enterocolitis (n = 1), and steroid-refractory acute graft-versus-host disease (GVHD) (n = 2). No transplant-related mortality was observed. At a median follow-up of 173 days (range, 52 - 1,015 days), all patients remained alive and in continuous complete remission with no active GVHD. Conclusions: In this single-center experience from a low-/middle-income country (LMIC), blinatumomab served as an effective bridge to HSCT, enabling MRD-negative remissions with favorable post-transplant outcomes. Viral reactivations and steroid-refractory GVHD were reported, underlining the need for robust surveillance. Broader access to blinatumomab and prospective studies are needed to validate these findings and to evaluate cost-effectiveness in LMICs.
- 2 October 2025
- Published by Springer Nature in International Journal of Hematology
- Vol. 123 (2) , 291-296
Tertiary prophylaxis with extended half-life factor prophylaxis: a model to reduce disability in low- and middle-income countries
Introduction The real-world data on treatment and outcome of hemophilia patients using extended half-life products in developing countries remain scarce. This is largely due to delayed diagnosis, poor joint outcomes, increased morbidity, and limited access to prophylaxis and newer products for treatment and prevention. Aim To analyze the response to extended half-life factor (EHL) prophylaxis in patients with severe hemophilia A and B with advanced arthropathy. Methods Patients with severe hemophilia A and B who received EHL factor concentrates for prophylaxis at our center were included in this analysis. Data collected included bleed frequency, joint involvement, annualized bleed rate (ABR), number of hospital visits, and Hemophilia Joint Health Score (HJHS) prior to prophylaxis. Breakthrough bleeds while on prophylaxis were also recorded. Results A total of 31 patients were started on EHL prophylaxis and followed up for a period ranging from 4 to 91 weeks. A reduction in the bleeding rate was noticed in all with significant reversal of target joints. Additionally, patients remained bleed-free during rehabilitation following joint surgery as well as psoas bleed-related compression neuropathy. Conclusion EHL prophylaxis appears to be an effective strategy even for patients with baseline target joints with significant arthropathy, thus reducing the extent of disability in these patients.
- 2 October 2025
- Published by Springer Nature in International Journal of Hematology
- Vol. 123 (2) , 291-296
Tertiary prophylaxis with extended half-life factor prophylaxis: a model to reduce disability in low- and middle-income countries
Introduction The real-world data on treatment and outcome of hemophilia patients using extended half-life products in developing countries remain scarce. This is largely due to delayed diagnosis, poor joint outcomes, increased morbidity, and limited access to prophylaxis and newer products for treatment and prevention. Aim To analyze the response to extended half-life factor (EHL) prophylaxis in patients with severe hemophilia A and B with advanced arthropathy. Methods Patients with severe hemophilia A and B who received EHL factor concentrates for prophylaxis at our center were included in this analysis. Data collected included bleed frequency, joint involvement, annualized bleed rate (ABR), number of hospital visits, and Hemophilia Joint Health Score (HJHS) prior to prophylaxis. Breakthrough bleeds while on prophylaxis were also recorded. Results A total of 31 patients were started on EHL prophylaxis and followed up for a period ranging from 4 to 91 weeks. A reduction in the bleeding rate was noticed in all with significant reversal of target joints. Additionally, patients remained bleed-free during rehabilitation following joint surgery as well as psoas bleed-related compression neuropathy. Conclusion EHL prophylaxis appears to be an effective strategy even for patients with baseline target joints with significant arthropathy, thus reducing the extent of disability in these patients.